(4-(bromomethyl)-1H-indol-1-yl)(phenyl)methanone | 1241048-04-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (4-(bromomethyl)-1H-indol-1-yl)(phenyl)methanone
• 英文别名: [4-(bromomethyl)indol-1-yl]-phenylmethanone
• CAS: 1241048-04-3
• 化学式: C₁₆H₁₂BrNO
• 分子量: 314.181
• InChiKey: GQOXUQIPHSXFSM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.22
• 重原子数：
  19.0
• 可旋转键数：
  2.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  22.0
• 氢给体数：
  0.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  (4-(bromomethyl)-1H-indol-1-yl)(phenyl)methanone 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 14.0h， 生成 2-(4-((2-pentyl-5-nitro-1H-benzo[d]imidazol-1-yl)methyl)-1H-indol-1-yl)benzonitrile
  参考文献：
  名称：

  Design, synthesis and biological evaluation of new 5-nitro benzimidazole derivatives as AT1 antagonists with anti-hypertension activities

  摘要：

  The design, synthesis, in vitro and in vivo evaluation of 5-nitro benzimidazole with 1,4-disubsituted or 1,5-disubsituted indole derivatives as novel angiotensin II receptor antagonist is outlined. Radioligand binding assays showed that 2-(4-((2-butyl-5-nitro-1H-benzo[d] imidazol-1-yl) methyl)-1H-indol-1-yl) benzoic acid, compound 3, displayed a high affinity for the angiotensin II type 1 receptor with IC50 value of 1.03 +/- 0.26 nM. The biological evaluation on spontaneously hypertensive rats and renal hypertensive rats showed that 3 could cause significant decrease on MBP in a dose dependent manner, whose maximal response lowered 30 mmHg of MBP at 5 mg/kg and 41 mmHg of MBP at 10 mg/kg after oral administration, and the significant antihypertensive effect lasted beyond 24 h, which is better than Losartan. Taken together 3 could be considered as an effective and durable anti-hypertension drug candidate. These encouraging results are deserved of further investigation towards its use for therapeutic benefit. (c) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.02.008
• 作为产物：
  描述：

  苯甲酰氯 在 4-二甲氨基吡啶 、 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 三乙胺 作用下， 以 四氯化碳 、 二氯甲烷 为溶剂， 生成 (4-(bromomethyl)-1H-indol-1-yl)(phenyl)methanone
  参考文献：
  名称：

  设计，合成和评估新型有效的血管紧张素II受体1拮抗剂。

  摘要：

  设计，合成和评估了一系列新的血管紧张素II（Ang II）受体1拮抗剂。所有化合物在放射性配体结合试验中均显示出与1型血管紧张素II受体的纳摩尔亲和力，并且可以显着降低自发性高血压大鼠（SHRs）的血压。由此可见，化合物2b在放射性配体结合测定中显示出与血管紧张素II 1型受体更高的亲和力结合，与厄贝沙坦的数量级相同，IC50值为1.26 +/- 0.08 nM。2b显示出有效且持久的降血压效果，在SHR中，最大降低反应为15 mg / kg时MBP为40.62 +/- 4.08 mmHg，10 mg / kg时为10 mg / kg 28.39 +/- 2.09 mmHg，39.56 + / -RHR中15 mg / kg时为4.83 mmHg，10 mg / kg时为29.05 +/- 2.20 mmHg，在SHR和RHR中，显着的降压作用持续超过12小时。在单剂量药代动力学实验中，口

  DOI：

  10.1016/j.ejmech.2016.07.023

文献信息

• N-Phenyl indole derivatives as AT1 antagonists with anti-hypertension activities: Design, synthesis and biological evaluation
  作者：Weibo Zhu、Xiaolu Bao、He Ren、Yajing Da、Dan Wu、Fuming Li、Yijia Yan、Li Wang、Zhilong Chen

  DOI：10.1016/j.ejmech.2016.03.021

  日期：2016.6

  synthesis, in vitro and in vivo evaluation of 6-substituted benzimidazole with 1, 4-disubsituted or 1, 5-disubsituted indole derivatives as novel angiotensin II receptor antagonists are outlined. Radioligand binding assays showed that several 6-substituted benzimidazole derivatives displayed high affinities binding to the angiotensin II type 1 receptor at the same order of magnitude to telmisartan. The

  概述了以1、4-二取代或1,5-二取代的吲哚衍生物作为新型血管紧张素II受体拮抗剂的6-取代苯并咪唑的设计，合成，体外和体内评价。放射性配体结合测定表明，几种6-取代的苯并咪唑衍生物以与替米沙坦相同的数量级显示出与血管紧张素II 1型受体的高亲和力结合。对自发性高血压大鼠的生物学评估显示，2- [4-[[2-n-丙基-4-甲基-6-（1-甲基苯并咪唑-2-基）苯并咪唑-1-基]甲基] -1H-吲哚- 1-yl]苯甲酸1c可以剂量依赖性方式导致MBP显着降低。口服给药后，其最大反应降低了5 mg / kg的MBP的53 mmHg和10 mg / kg的MBP的64 mmHg，并且显着的降压作用持续了24小时以上，比氯沙坦和替米沙坦都好。旨在确定急性毒性的一项研究表明，1c的急性毒性较低，重量没有明显变化，也没有明显的不良反应。令人鼓舞的结果使1c成为一种有效且持久的抗高血压药物候选者，值得在治疗方面进行进一步研究。
• 一种吗啉类四氮唑化合物及其制备方法和应用
  申请人：东华大学

  公开号：CN103435605B

  公开（公告）日：2016-04-06

  本发明涉及一种吗啉类四氮唑化合物及其制备方法和应用，化合物的结构式为：制备方法包括：由苯甲酰基保护的溴甲基吲哚与(R,S)-2,6-二甲基吗啉，通过亲核取代反应得到含有吗啉环、甲基吲哚、苯甲酰基三部分结构的化合物；然后在碱性条件下水解脱去保护基，得到只含有吗啉环和甲基吲哚结构的化合物；该化合物与邻氟苯腈在碳酸钾和DMF存在的条件下，反应生成含有邻氰基苯结构的产物。本发明能更好的抑制AngII与AT1受体结合，有明显的降压作用，最大降压值达到42mmHg，且有效降压时间可维持24小时以上，合成路线短，原料易得，反应收率较高，具有发展为高效、长效、价廉的降压新药开发前景。
• Synthesis, Anti-hypertensive Effect of a Novel Angiotensin II AT1 Receptor Antagonist and its Anti-tumor Activity in Prostate Cancer
  作者：Y.-J. Da、W.-D. Yuan、L.-F. Zhu、Z.-L. Chen

  DOI：10.1055/s-0032-1329952

  日期：——

  Since the first non-peptide Ang II receptor antagonist was originally reported, it has become the most common target in the development of new treatments for hypertension. In recent years, all components of the classical RAS have been reported in the prostate, these results suggest the possibility that ARB is a novel therapeutic class of agents for prostate cancer. In this study, a new compound 2-(4-((2-propyl-5-nitro-1H-benzo[d]imidazol-1-yl) methyl)-1H-indol-1-yl) benzoic acid was synthesized and evaluated as a novel angiotensin II AT(1) receptor antagonist by radioligand binding assays, anti-hypertensive assays in vivo and oral acute toxicity test. MTT assays and tests in nude mice were used to demonstrate its anti-tumor activity. This new compound showed high affinity to AT(1) receptor and anti-hypertensive activity in spontaneously hypertensive rats and renal hypertensive rats. Moreover, in human prostate cancer cells and in athymic nude mice bearing human prostate cancer cells, we observed this new compound had an efficient antiproliferative activity in vitro and anti-tumor activity in vivo. The preliminary pharmacological characteristics with oral acute toxicity test suggested that this new compound can be considered as a candidate for both anti-hypertensive and antitumor drug.